English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Meeting Abstract

GLINT: GlucoCEST in neoplastic tumors at 3 T – preliminary application in glioma patients using optimized preparation, imaging, and post-processing

MPS-Authors
/persons/resource/persons216025

Herz,  K
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons215996

Deshmane,  A
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons84187

Scheffler,  K
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons214560

Zaiss,  M
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Herz, K., Lindig, T., Deshmane, A., Bender, B., Golay, X., Ernemann, U., et al. (2019). GLINT: GlucoCEST in neoplastic tumors at 3 T – preliminary application in glioma patients using optimized preparation, imaging, and post-processing. In ISMRM 27th Annual Meeting & Exhibition.


Cite as: http://hdl.handle.net/21.11116/0000-0003-96ED-9
Abstract
Dynamic glucoCEST at clinical field strengths is very challenging due to the low effect size. Here, we present a saturation, imaging and post-processing protocol for minimizing possible artifacts to detect dynamic CEST effects reliably, and demonstrate the application in two glioblastoma patients at 3 T.